Risk of Delayed Human Papillomavirus Vaccination in Inner-City Adolescent Women
| Autor: | Ken Peake, Maoxin Wu, Nicolas F. Schlecht, Anne Nucci-Sack, Arnold H. Szporn, Angela Diaz, Viswanathan Shankar, Robert D. Burk, Howard D. Strickler |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Longitudinal study Adolescent Urban Population Anal Canal Cervix Uteri Polymerase Chain Reaction Medication Adherence Young Adult Major Articles and Brief Reports 03 medical and health sciences Adolescent medicine 0302 clinical medicine 030225 pediatrics Humans Immunology and Allergy Medicine Longitudinal Studies Papillomavirus Vaccines 030212 general & internal medicine Child Papillomaviridae Immunization Schedule business.industry Obstetrics Incidence (epidemiology) Papillomavirus Infections Vaccination Hazard ratio virus diseases Anal Infection United States Confidence interval Regimen Infectious Diseases DNA Viral Immunology Female business |
| Zdroj: | Journal of Infectious Diseases. 214:1952-1960 |
| ISSN: | 1537-6613 0022-1899 |
| Popis: | Background. Uptake of human papillomavirus (HPV) vaccine in the United States is slow, and the effectiveness of the vaccine has not been assessed in high-risk adolescent populations. Methods. We conducted a longitudinal study of 1139 sexually active, inner-city adolescent women receiving the 3-dose quadrivalent (4vHPV) vaccine. Cervical and anal specimens collected semiannually were tested using an L1-specific polymerase chain reaction assay. Postvaccination incidence of 4vHPV vaccine and nonvaccine HPV types, and risk of cervical cytological abnormalities, were assessed in relation to time to completion of all 3 vaccine doses. Results. Compared to vaccine naive women at enrollment, vaccinated women had significantly lower incidence rate ratios of cervical infection with HPV6/11/16/18 (0.2; 95% confidence interval [CI], .1–.4) and the related types HPV31 and HPV45 (0.4 [95% CI, .2–1.0] and 0.3 [95% CI, .1–.6], respectively), as well as significantly lower incidence rate ratios of anal infection with HPV6/11/16/18 (0.4; 95% CI, .2–.7). Notably, we observed higher risks of cervical HPV6/11/16/18 infection (hazards ratio [HR], 2.9; 95% CI, 1.0–8.0) and associated cytological abnormalities (HR, 4.5; 95% CI, .7–26.0) among women immunized at ≥15 years of age who took ≥12 months (vs |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|